Clinical trial Recruiting at 1 site Interventional Ages 18 to 75 Women only

Treatment for breast cancer that has spread to the liver using a new ablation technique

Official title: A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases

Run by Ruijin Hospital · NCT06567353 · Data updated 2026-11-12

This study is testing a new treatment method for breast cancer that has spread to the liver to see if it works better than the standard approach.

More Metastasis trials

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexWomen only
Enrollment10 (estimated)
SponsorRuijin Hospital
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedDecember 9, 2024
Main results expectedJuly 2027
Study endsDecember 2027
Registry record updatedMarch 14, 2025
Trial IDNCT06567353 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18-75 with pathologically confirmed breast cancer liver metastases who are unable to tolerate or refuse surgical resection.

Probably not a fit

Patients with severe liver dysfunction, widespread metastasis, or other significant health issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety and effectiveness of a multi-mode integrated ablation system for treating breast cancer liver metastases. It is a single-center, parallel-controlled study involving 10 participants, with half receiving the experimental treatment and the other half undergoing conventional radiofrequency ablation. The study will assess the impact of the new technique on systemic anti-tumor immunity, comparing outcomes between the two groups over a defined treatment and follow-up period.

Why it matters

Potential benefit: If successful, this treatment could provide a more effective option for patients with breast cancer liver metastases who cannot undergo surgery.

How similar studies have gone: While similar approaches have been explored, this specific multi-mode thermophysical immunotherapy technique is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 18-75 years, female gender;
2. Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;
3. The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;
4. At least an interval of 1 month since the last local treatment;
5. Child-Pugh class A or B;
6. ECOG PS score ≤2, with an expected survival of \>3 months.

Exclusion Criteria:

1. Liver function Child-Pugh class C;
2. Systemic widespread metastasis, with an expected survival of \< 3 months;
3. History of esophageal (gastric fundus) variceal bleeding within the past month;
4. Dysfunction or failure of vital organs;
5. Presence of an active infection;
6. Irreparable coagulation abnormality;
7. Refractory massive ascites, pleural effusion or cachexia;
8. Pregnancy, altered consciousness or patients unable to cooperate with treatment;
9. Previously participated in other clinical studies and still within the follow-up period;
10. Any other factors deemed inappropriate for inclusion or that may affect the patient's participation in the study, as determined by the investigator.

Where it's running

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.